Keywords
Placental Growth Factor (PlGF)
Biomarkers
Angiogenesis
Immunoassay
How to Cite
Abstract
Introduction: Preeclampsia is a hypertensive disorder of pregnancy, which, with an incidence of 2% to 5%, constitutes the leading cause of perinatal morbidity and mortality worldwide. Its pathophysiology is associated with an imbalance between proangiogenic (placental growth factor [PlGF]) and antiangiogenic (soluble MSF-like tyrosine kinase-1 [sFlt-1]) factors, with a predominant increase in the latter. Consequently, diagnostic tests have been developed to predict, diagnose and evaluate the prognosis of adverse events. Objectives: To compare the diagnostic utility of the Elecsys sFlt-1/PlGF ratio (Roche) and the Triage PlGF test (Quidel) and to verify the analytical accuracy of Triage PlGF (Quidel). Materials and methods: A prospective study was carried out including samples from pregnant patients with suspected preeclampsia, received at the Laboratorio Central del Hospital Italiano (Buenos Aires, Argentina). Samples were processed by both tests. Results: The correlation between PlGF concentrations was demonstrated from the scatter plot, and a Spearman correlation coefficient of 0.88 [p<0.001] was obtained. The Bland-Altman plots showed no concordance between PlGF concentrations. The repeatability and intermediate precision of the Triage PlGF assay were statistically accepted. Conclusions: The Elecsys sFlt-1/PlGF ratio and the Triage PlGF test are comparable assays for the diagnosis of preeclampsia, verifying the accuracy of the latter.
References
1. Dröge LA, Perschel FH, Stütz N, Gafron A, Frank L, Busjahn A, et al. Prediction of Preeclampsia-Related Adverse Outcomes With the sFlt-1 (Soluble fms-Like Tyrosine Kinase1) / PlGF (Placental Growth Factor)-
Ratio in the Clinical Routine. Hypertension. 2021;77(2) 461-471, https://doi.org/10.1161/HYPERTENSIONAHA.120.15146
2. Agrawal S, Cerdeira AS, Redman C, Vatish M. Meta-Analysis and Systematic Review to Assess the Role of Soluble FMS-Like Tyrosine Kinase-1 and Placenta Growth Factor Ratio in Prediction of Preeclampsia: The SaPPPhirE Study. Hypertension. 2018;71(2):306-16, https://doi.org/10.1161/HYPERTENSIONAHA.117.10182
3. Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. Obstet Gynecol. 2020;135(6):e237-60, https://doi.org/10.1097/AOG.0000000000003891
4. Karpova NS, Dmitrenko OP, Budykina TS. Literature Review: The sFlt1/PlGF Ratio and Pregestational Maternal Comorbidities: New Risk Factors to Predict Pre-Eclampsia. Int J Mol Sci. 2023;24(7), https://doi.org/10.3390/ijms24076744
5. Stepan H, Hund M, Andraczek T. Combining Biomarkers to Predict Pregnancy Complications and Redefine Preeclampsia: The Angiogenic- Placental Syndrome. Hypertension. 2020;75(4):918-26, https://doi.org/10.1161/HYPERTENSIONAHA.119.13763
6. Álvarez-Fernández I, Prieto B, Álvarez FV. Preeclampsia. Rev lab clín. 2016;9(2):81-9, https://doi.org/10.1016/j.labcli.2016.04.002
7. Lapidus A, López N, Malamud J, Nores J, Papa S. Estados hipertensivos y embarazo. Consenso FASGO. Federación Argentina de Sociedades de Ginecología y Obstetricia; 2017. Disponible en: https://www.fasgo.org.ar
8. Sovio U, Gaccioli F, Cook E, Hund M, Charnock-Jones DS, Smith GCS. Prediction of Preeclampsia Using the Soluble fms-Like Tyrosine Kinase 1 to Placental Growth Factor Ratio: A Prospective Cohort Study of Unselected Nulliparous Women. Hypertension. 2017;69(4):731-8, https://doi.org/10.1161/HYPERTENSIONAHA.116.08620
9. Chaemsaithong P, Gil MM, Chaiyasit N, Cuenca-Gomez D, Plasencia W, Rolle V, et al. Accuracy of placental growth factor alone or in combination with soluble fms-like tyrosine kinase-1 or maternal factors in detecting preeclampsia in asymptomatic women in the second and third trimesters: a systematic review and meta-analysis. Am J Obstet Gynecol. 2023;229(3):222-47, https://doi.org/10.1016/j.ajog.2023.03.032
10. Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennström M, et al. Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. N Engl J Med. 2016;374(1):13-22, https://doi.org/10.1056/NEJMoa1414838
11. Liu Y, Zhao Y, Yu A, Zhao B, Gao Y, Niu H. Diagnostic accuracy of the soluble Fms-like tyrosine kinase-1/placental growth factor ratio for preeclampsia: a meta-analysis based on 20 studies. Arch Gynecol Obstet. 2015;292(3):507-18, https://doi.org/10.1007/s00404-015-3671-8
12. Creswell L, O’Gorman N, Palmer KR, da Silva Costa F, Rolnik DL. Perspectives on the Use of Placental Growth Factor (PlGF) in the Prediction and Diagnosis of Pre-Eclampsia: Recent Insights and Future Steps. IJWH. 2023;15:255-71, https://doi.org/10.2147/IJWH.S368454
13. National Institute for Health and Care Excellence (NICE). PLGF-based testing to help diagnose suspected preterm pre-eclampsia. HealthTech Guidance [HTG630]; 2022. Disponible en: https://www.nice.org.uk/guidance/htg630
14. Schober P, Boer C, Schwarte LA. Correlation Coefficients: Appropriate
Use and Interpretation. Anesth Analg. 2018;126(5):1763–8, https://doi.org/10.1213/ANE.0000000000002864
15. Landis JR, Koch GG. The measurement of observer agreement for cate gorical data. Biometrics. 1977;33(1):159–74.
16. Chappell LC, Duckworth S, Seed PT, Griffin M, Myers J, Mackillop L, et al. Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study. Circulation. 2013;128(19):2121–31, https://doi.org/10.1161/CIRCULATIONAHA.113.003215
17. Duhig KE, Myers J, Seed PT, Sparkes J, Lowe J, Hunter RM, et al. Placental growth factor testing to assess women with suspected pre-eclampsia: a multicentre, pragmatic, stepped-wedge cluster-randomised controlled trial. Lancet. 2019;393(10183):1807–18, https://doi.org/10.1016/S0140-6736(18)33212-4
18. Verlohren S, Herraiz I, Lapaire O, Schlembach D, Zeisler H, Calda P, et al. New gestational phase-specific cutoff values for the use of the soluble fms-like tyrosine kinase-1/placental growth factor ratio as a diagnostic test for preeclampsia. Hypertension. 2014;63(2):346–52, https://doi.org/10.1161/HYPERTENSIONAHA.113.01787
19. Knudsen UB, Kronborg CS, von Dadelszen P, Kupfer K, Lee SW, Vittinghus E, et al. A single rapid point-of-care placental growth factor determination as an aid in the diagnosis of preeclampsia. Pregnancy Hypertens. 2012;2(1):8–15, https://doi.org/10.1016/j.preghy.2011.08.117
20. Benton SJ, Hu Y, Xie F, Kupfer K, Lee SW, Magee LA, et al. Angiogenic
factors as diagnostic tests for preeclampsia: a performance comparison between two commercial immunoassays. Am J Obstet Gynecol. 2011;205(5):469.e1–8, https://doi.org/10.1016/j.ajog.2011.06.058
21. Stepan H, Hund M, Gencay M, Denk B, Dinkel C, Kaminski WE, et al. A comparison of the diagnostic utility of the sFlt-1/PlGF ratio versus PlGF alone for the detection of preeclampsia/HELLP syndrome. Hypertens Pregnancy. 2016;35(3):29-305, https://doi.org/10.3109/10641955.2016.1141214
22. Cheng YKY, Poon LCY, Shennan A, Leung TY, Sahota DS. Inter-manufacturer comparison of automated immunoassays for the measurement of soluble FMS-like tyrosine kinase-1 and placental growth factor. Pregnancy Hypertens. 2019;17:165-71, https://doi.org/10.1016/j.preghy.2019.06.004
23. Hurrell A, Beardmore-Gray A, Duhig K, Webster L, Chappell LC, Shennan AH. Placental growth factor in suspected preterm pre-eclampsia: a review of the evidence and practicalities of implementation. BJOG. 2020;127(13):1590-7, https://doi.org/10.1111/1471-0528.16425
24. Miller JJ, Higgins V, Melamed N, Hladunewich M, Ma L, Yip PM, et al. Clinical Validation of the sFlt-1:PlGF Ratio as a Biomarker for Preeclampsia Diagnosis in a High-Risk Obstetrics Unit. J Appl Lab Med. 2023;8(3):457-68, https://doi.org/10.1093/jalm/jfad003
25. Lacunza Paredes RO, Pacheco Romero J. Preeclampsia de inicio temprano y tar dío: una antigua enfermedad, nuevas ideas. Rev Peru Ginecol Obstet. 2015;60(4):351–61.